Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumorsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether stool bacteria differ across gastric tumor types and healthy people. Researchers compared gut microbiota in gastric adenocarcinoma, its diffuse and intestinal subtypes, and gastrointestinal stromal tumors (GIST). They sequenced the 16S ribosomal RNA gene from DNA in stool samples. Six hypervariable regions were amplified on the Ion PGM platform. Richness (Chao1), diversity (Shannon), composition (Bray-Curtis), and differential abundance (ALDEx2) were then compared between groups.
Who was studied?
The cohort was 65 Finnish adults: 29 with gastric adenocarcinoma, 23 with GIST, and 13 healthy controls. Samples came from surgical clinics in Helsinki, Finland. Adenocarcinoma was split into diffuse, intestinal, and mixed subtypes. Patients had received no antimicrobials for six months and no cancer treatment before sampling. Controls were younger than patients, which the authors flag as a possible confounder. Diffuse patients averaged 69 years, intestinal patients 75 years.
What were the most important findings?
Enterobacteriaceae abundance was significantly higher in all tumor groups: diffuse, intestinal, and GIST. Bacteroidetes, Lactobacillaceae, and Oscillibacter were lower in cancer patients versus controls. Diffuse adenocarcinoma had the lowest microbiota diversity, and only this subtype showed significantly lower Bifidobacteriaceae. Adenocarcinoma patients also had lower Lachnoclostridium, Bifidobacterium, Parabacteroides, and Barnesiella. Beta-diversity differed significantly between controls and every tumor subgroup. Richness (Chao1) was significantly lower in cancer patients, but the Shannon diversity drop was not significant.
What are the greatest implications of this study?
Higher gut Enterobacteriaceae appears across all gastric tumor types, so it may serve as a shared marker of gastric malignancy. This is the first reported gut microbiota analysis in GIST patients. Lower diversity in diffuse adenocarcinoma may reflect its aggressive, poorly differentiated biology or advanced stage. It could be explored as a prognostic signal. The design is observational with a small, age-mismatched control group, so these associations do not establish that microbes cause the tumors.